A prospective clinical study published in JCO Precision Oncology confirms that KYAN Technologies' Optim.AI™ platform accurately predicts clinical response in relapsed/refractory non-Hodgkin lymphoma (R/R-NHL), including hard-to-treat subtypes where genomic testing often provides limited guidance. The study, conducted across 117 patients at two tertiary cancer centers, represents the largest published cohort to date using an ex vivo functional precision medicine platform in lymphoma.
Clinical Validation Results
The prospective validation study demonstrated meaningful clinical utility with both objective response rates and Kaplan-Meier survival outcomes showing significantly longer progression-free survival in patients treated with combinations prioritized by the platform. Key findings include 74.5% test accuracy in predicting clinical response and 59% objective response rates in patients treated with platform-guided combinations.
Notably, the study showed a three-fold improvement in progression-free survival compared to prior treatment lines. Two-year survival analysis revealed a statistically significant benefit over salvage therapy (P = 0.0191), demonstrating that functionally guided therapies delivered not just predictive concordance, but measurable clinical benefit in a real-world setting.
Platform Technology and Mechanism
Optim.AI™ directly measures how live tumor cells respond to therapy using a proprietary experimental design. The platform tests hundreds of clinically relevant drug treatments simultaneously, including standard-of-care regimens, off-label therapies with known safety profiles, and novel options. These treatments are ranked based on predicted treatment response, providing oncologists with real-time guidance tailored to the biology of each tumor.
"This study reinforces the scientific rigor behind the platform by showing we can deliver reproducible, clinically concordant results across a large cohort of real patient samples," said Edward K. Chow, PhD, KYAN Technologies' Chief Scientific Officer. The platform's functional, patient-specific readout complements genomic and transcriptomic tools by providing a clinically actionable layer of insight.
Clinical Impact and Future Deployment
The results underscore the broader potential of functional precision medicine to inform treatment decisions and combination design across oncology. By capturing how each patient's tumor responds to a breadth of drug regimens, the platform not only guides clinical care but also offers insights that can support off-label strategy, clinical trial selection, and future drug development.
"This study marks a defining milestone in Optim.AI™'s journey toward clinical adoption. With our clinical and analytical validation now published in a peer-reviewed journal, we're positioned to scale the platform in the U.S., starting with CLIA deployment and expanding through partnerships with leading clinicians and institutions," said Hugo Saavedra, Chief Executive Officer of KYAN Technologies.
Collaborative Research Framework
The study benefited from essential contributions from clinical collaborators at the National University of Singapore (NUS), National University Hospital (NUH), and Singapore General Hospital (SGH). These partnerships helped shape a platform that delivers timely, reliable, and actionable guidance for both physicians and patients in the challenging treatment landscape of relapsed/refractory non-Hodgkin lymphoma.
KYAN Technologies, headquartered in Singapore, is expanding its U.S. presence to advance clinical deployment and strategic collaborations across oncology research and care, supporting both patient care and drug development initiatives.
